Literature DB >> 27326008

The medical treatment of endomyocardial fibrosis in 2009.

Kunju M Subair1, Prabha Nini Gupta1, K Suresh1, K R Santhosh1, Preetham Kumar Francis1, Thomas John1, Preeti Sara George2.   

Abstract

OBJECTIVES: To study the natural history of medically treated patients with endomyocardial fibrosis (EMF) and to see whether the usage of common drugs affected survival.
DESIGN: A real-world all-comers analysis with follow-up.
SETTING: A teaching hospital. ANALYSIS: Cox proportional hazards multiple regression and Kaplan-Meier curves for survival with both univariate and multivariate analysis.
RESULTS: The mean age of this population was 40.5±5 years at first symptom. The mortality was also less than previous reports at 10.38%. The dominant type of EMF was dominant left ventricular EMF in 49, right ventricular EMF in 52 and biventricular EMF in 53. On univariate analysis by Kaplan-Meier curves and log-rank test patients on warfarin had a better survival (at 5, 10 and 15 years-97.3, 87.54% and 87.54%, respectively) compared with no warfarin at 5, 10 and 15 years (91.37%, 88.9% and 66.68%), log rank test NS. On multivariate analysis when sex, the presence of complications, use of ACE inhibitors, use of aldactone, use of digoxin, frusemide and warfarin and age (age at entering the study) were entered into the analysis, the following results were obtained-men had a shorter time to death. Furthermore, when patients taking aldactone and those not taking aldactone were examined it was found that those on aldactone had a higher mortality and shorter time to death.
CONCLUSION: On analysis of the usage of warfarin, those not on it had a shorter time to death; likewise did older patients.

Entities:  

Keywords:  ACE inhibitors; anticoagulation; cardiomyopathy restrictive; diuretics; endomyocardial fibrosis; medical treatment; natural history; survival

Year:  2011        PMID: 27326008      PMCID: PMC4898559          DOI: 10.1136/ha.2010.003525

Source DB:  PubMed          Journal:  Heart Asia        ISSN: 1759-1104


  3 in total

1.  Clinical course of endomyocardial fibrosis.

Authors:  P N Gupta; M S Valiathan; K G Balakrishnan; C C Kartha; M K Ghosh
Journal:  Br Heart J       Date:  1989-12

Review 2.  Endomyocardial fibrosis in Uganda (Davies' disease). 1. An epidemiologic, clinical, and pathologic study.

Authors:  D H Connor; K Somers; M S Hutt; W C Manion; P G D'Arbela
Journal:  Am Heart J       Date:  1967-11       Impact factor: 4.749

3.  Survival after first presentation with endomyocardial fibrosis.

Authors:  P G D'Arbela; T Mutazindwa; A K Patel; K Somers
Journal:  Br Heart J       Date:  1972-04
  3 in total
  3 in total

1.  Endomyocardial fibrosis in a non-tropical patient who presented with chest pain mimicking ACS and left ventricular thrombus, case report.

Authors:  Ahmad S Matarneh; Yousef M Ali Hailan; Sabir Abdul Karim; Maryam A Al Kuwari; Wafer A Dabdoob
Journal:  Clin Case Rep       Date:  2022-05-23

2.  Endomyocardial fibrosis of the right ventricle in a patient with schistosomiasis: a case report.

Authors:  Cristhian Espinoza Romero; Ivna Cunha Vieira Lima; Viviane Tiemi Hotta; Edimar Alcides Bocchi; Vera Maria Cury Salemi
Journal:  Eur Heart J Case Rep       Date:  2022-07-28

3.  Geographical variation in the clinical presentation of endomyocardial fibrosis in India?

Authors:  Prabha Nini Gupta; Subair M Kunju; Baiju Rajan; A George Koshy; Sunitha Vishwanathan; Preeti Sara George; Praveen Velappan
Journal:  Indian Heart J       Date:  2017-01-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.